Abstract
Introduction Monitoring of COVID-19 vaccine effectiveness (VE) is needed to inform vaccine policy. We estimated VE of primary vaccination, and first and second booster vaccination, against SARS-CoV-2 infection overall, and in four risk groups defined by age and medical risk condition, in the Delta and Omicron BA.1/BA.2 periods.
Methods VASCO is an ongoing prospective cohort study among vaccinated and unvaccinated Dutch adults. The primary endpoint was a self-reported positive SARS-CoV-2 test during 12 July 2021-6 June 2022. Participants with a prior SARS-CoV-2 infection, based on a positive test or serology, were excluded. We used Cox proportional hazard models with vaccination status as time-varying exposure and adjustment for age, sex, educational level, and medical risk condition. We stratified by Delta and Omicron BA.1/BA.2 periods, risk group, and time since vaccination.
Results 37,170 participants (mean age 57 years) were included. In the Delta period, VE <6 weeks after primary vaccination was 80% (95%CI 69-87) and decreased to 71% (65-77) after 6 months. VE increased to 96% (86-99) shortly after the first booster vaccination. In the Omicron period these estimates were 46% (22-63), 25% (8-39) and 57% (52-62), respectively. VE was 50% (34-62) <6 weeks after a second booster vaccination in participants aged ≥60 years. For the Omicron period, an interaction term between vaccination status and risk group significantly improved the model (p<0.001), with generally lower VEs for those with a medical risk condition.
Conclusions Our results show the benefit of booster vaccinations against infection, also in risk groups, although the additional protection wanes quite rapidly.
Summary This prospective cohort study contributes to vaccine policy of COVID-19 by showing the benefit of booster vaccination in preventing SARS-CoV-2 infections, also in risk groups in which protection was generally lower, although the additional protection was rather short-lived.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://trialsearch.who.int/Trial2.aspx?TrialID=NL9279
Funding Statement
This study was funded by the Dutch Ministry of Health, Welfare and Sport
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical Ethics Committee of the Stichting Beoordeling Ethiek Biomedisch Onderzoek, Assen, the Netherlands, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available in aggregated and anonymized form upon reasonable request to the authors.
List of abbreviations
- BEBO
- Beoordeling Ethiek Biomedisch Onderzoek
- CIMS
- COVID-19 vaccination Information and Monitoring System
- Ig
- immunoglobulin
- N
- nucleocapsid protein
- RIVM
- National Institute of Public Health and the Environment
- VASCO
- VAccine Study COvid-19
- VE
- vaccine effectiveness
- WHO
- World Health Organization